A group from enGenes Biotech GmbH, Muthgasse 11, 1190 Vienna, Austria, etc. has reported about a drug delivery system using shiga toxin B subunit in cancer therapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157870/
Shiga Toxin B subunit (STxB) is a kind of lectin which is specific to the glycosphingolipid (GSL) globotriaosylceramide (Gb3) on target tumore cells. Monomethyl auristatin E (MMAE) was conjugated to StxB (STxB-MMAE), and its tumore cell-killing capability was evakluated with using two types of cells, human colorectal adenocarcinoma cell lines—HT-29 (Gb3+) and LS-174 (Gb3-). The STxB–MMAE conjugate induced uptake and release of the MMAE drug in Gb3-positive tumor cells, reaching 94% of HT-29 cell elimination at 72 h post-treatment.
